-- Solid first quarter performance broadly in line with guidance,
underpinned by resilient demand across core in-line brands
-- Commercial execution and late-stage pipeline investments on schedule,
including first approval for ORZEYFULTM (oveporexton) in China, setting
the foundation for next wave of medicines
-- No change to FY2026 full-year forecast and management guidance
OSAKA, Japan--(BUSINESS WIRE)--July 30, 2026--
Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined execution and operational momentum. Takeda leveraged the resilient performance of its core in-line portfolio to support its long-term strategy, advancing commercial launch preparations and driving critical R&D pipeline milestones. With a clear operational trajectory established in the first quarter and under a new operating model, Takeda remains on track to deliver its strategic and financial commitments for the fiscal year.
FY2026 First Quarter Highlights
-- Revenue increased by +10.2% versus the prior-year period on an actual
exchange rate $(AER)$ basis and decreased by -0.5% on a Constant Exchange
Rate (CER) basis as the negative impact of the loss of exclusivity of
VYVANSE$(R)$ was largely offset by growth from core in-line brands.
-- Core Operating Profit increased by +11.5% on an AER basis and decreased
by -0.5% on a CER basis, reflecting continued growth investments
supported by the transformation program.
-- Reported Operating Profit increased by +9.1% on an AER basis.
-- Core EPS increased by +1.5% at AER and decreased by -11.8% at CER,
while Reported EPS decreased by -9.8% YoY.
-- Adjusted Free Cash Flow amounted to JPY 68.6 billion.
-- Launch preparations for key late-stage pipeline assets (ORZEYFUL,
rusfertide and zasocitinib) are progressing on schedule, with the first
approval for ORZEYFUL achieved in China.
-- FY2026 full-year outlook remains unchanged.
-- A Capital Markets Day will be held on December 11, 2026, in Tokyo,
Japan.
Takeda President and Chief Executive Officer, Julie Kim, commented:
"Our solid performance this quarter marks a good start to the fiscal year and keeps us on track to achieve our full-year targets.
"This quarter's results reflect our unwavering commitment to financial discipline and the progressing execution of our enterprise transformation. The efficiencies unlocked by this ongoing program are directly fueling our highest priorities in Horizon One in our two-horizon growth strategy: the successful launch of three medicines that have the potential to be blockbuster brands, the advancement of our late-stage pipeline, the enduring resilience of our core in-line portfolio and new capabilities and efficiencies gained through transformation. We look forward to sharing the detailed strategic roadmap for these two growth horizons at our Capital Markets Day in December."
Takeda Chief Financial Officer, Milano Furuta, commented:
"Our first-quarter performance is tracking consistently with management guidance, with the resilience of our core in-line brands largely offsetting our mature portfolio decline, and OPEX savings through the transformation program being strategically reinvested to fund future growth opportunities. Our full-year forecast and guidance remain unchanged."
FINANCIAL HIGHLIGHTS for First Quarter Results ended June 30, 2026
(Billion yen, except percentages and per share amounts)
------------------------------------------------------------------------
FY2026 Q1 FY2025 Q1
Item (Billion JPY) (Billion JPY) YoY (AER)
---------------------------- -------------- -------------- ---------
Revenue 1,219.9 1,106.7 +10.2%
----------------------------- -------------- -------------- ---------
Operating Profit 201.4 184.6 +9.1%
----------------------------- -------------- -------------- ---------
Margin 16.5% 16.7% -0.2pp
----------------------------- -------------- -------------- ---------
Net Profit 113.2 124.2 -8.9%
----------------------------- -------------- -------------- ---------
EPS (Yen) 72 79 -9.8%
----------------------------- -------------- -------------- ---------
Operating Cash Flow 127.6 215.4 -40.8%
----------------------------- -------------- -------------- ---------
Adjusted Free Cash Flow
(Non-IFRS) 68.6 190.1 -63.9%
----------------------------- -------------- -------------- ---------
Core (Non-IFRS)
(Billion yen, except percentages and per share amounts)
-----------------------------------------------------------------
Item FY2026 Q1 FY2025 Q1 YoY (AER) YoY (CER)
------------------ ---------- ---------- --------- ---------
Revenue 1,219.9 1,106.7 +10.2% -0.5%
------------------- ---------- ---------- --------- ---------
Operating Profit 358.9 321.8 +11.5% -0.5%
------------------- ---------- ---------- --------- ---------
Margin 29.4% 29.1% +0.3pp
------------------- ---------- ---------- --------- ---------
Net Profit 242.9 237.0 +2.5% -10.9%
------------------- ---------- ---------- --------- ---------
EPS (Yen) 154 151 +1.5% -11.8%
------------------- ---------- ---------- --------- ---------
FY2026 Full-year Forecast and Guidance
There are no changes to the FY2026 forecast and management guidance announced
on May 13, 2026.
(Billion yen, except percentages and per share amounts)
------------------------------------------------------------------------------
Item FY2026 FORECAST FY2026 MANAGEMENT
GUIDANCE Core change at CER
(Non-IFRS)
--------------------------- --------------- ----------------------------
Revenue 4,640.0 --
--------------------------- --------------- ----------------------------
Core Revenue (Non-IFRS) 4,640.0 Low-single digit % decline
--------------------------- --------------- ----------------------------
Operating Profit 420.0 --
--------------------------- --------------- ----------------------------
Core Operating Profit 1,160.0 5% to 8% decline
(Non-IFRS)
--------------------------- --------------- ----------------------------
Net Profit 166.0 --
--------------------------- --------------- ----------------------------
EPS (Yen) 104 --
--------------------------- --------------- ----------------------------
Core EPS (Yen) (Non-IFRS) 472 Mid-teens % decline
--------------------------- --------------- ----------------------------
Adjusted Free Cash Flow 650.0 -- 750.0 --
(Non-IFRS)
--------------------------- --------------- ----------------------------
Annual dividend per share 204 --
(Yen)
--------------------------- --------------- ----------------------------
Pipeline Progress Building the Foundation for Future Growth
Takeda's next-generation growth engine is anchored by three, high-potential, late-stage pipeline assets expected to obtain regulatory approvals in the U.S. and other key regions in the coming year. While this represents a pivotal period of strategic investment and commercial launch execution, Takeda is positioned to deliver tangible milestones over the next 12 to 24 months. By establishing a track record of launch excellence today, Takeda is securing the foundation that will underpin the Company's sustained, long-term growth and meaningful impact for patients globally.
ORZEYFUL
-- An orexin receptor agonist with a first-in-class mechanism of action,
designed to address the orexin deficiency that causes narcolepsy type 1
(NT1).
-- The first approval of oveporexton was recently granted in China under
the brand name ORZEYFUL.
-- New drug applications are currently under review in the United States
and Japan.
-- Preparations for the expected launches in the U.S., Japan and China in
the second half of the year are well underway.
-- At SLEEP 2026, Takeda presented Phase 3 clinical trial results for
ORZEYFUL demonstrating improvements in daily functioning, cognition and
nighttime sleep in patients with narcolepsy type 1.
Rusfertide
-- A potential first-in-class hepcidin mimetic for the treatment of adults
with the blood cancer polycythemia vera (PV).
-- Demonstrated significant improvements in hematocrit control and
phlebotomy reduction for patients with PV in a Phase 3 clinical trial.
-- Granted Priority Review by the U.S. FDA, Takeda is prepared for a
commercial U.S. launch expected in the second half of 2026.
Comments